TLSA TLSA
Company Profile ↓Company Overview
TLSA (TLSA) is a publicly traded company listed on with a market capitalization of $119.30M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -57.51% |
| 6 Months: | -32.19% |
| 3 Months: | -30.77% |
| 1 Month: | -21.43% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 59.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | - | - | - | - |
| Gross Profit | 0 | - | - | - | - |
| Operating Expenses | - | 14.59M | 17.98M | 15.79M | 21.13M |
| Operating Income | - | -14.59M | -17.98M | -15.79M | -21.13M |
| EBITDA | - | -15.31M | -17.14M | -16.62M | -18.18M |
| Interest Expense | - | 38.00K | 10.00K | 6.00K | 18.00K |
| Pretax Income | - | -15.40M | -17.24M | -16.75M | -18.43M |
| Tax Provision | - | 0 | 449.00K | -4.88M | 0 |
| Net Income | - | -15.40M | -17.69M | -11.86M | -18.43M |
| Diluted EPS | - | -0.15 | -0.17 | -0.11 | -0.16 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 26.48M | 12.18M | 11.28M | 11.49M |
| Current Assets | - | 24.28M | 7.34M | 7.51M | 8.55M |
| Cash & Equivalents | - | 18.12M | 1.18M | 3.72M | 4.01M |
| Inventory | - | - | - | - | - |
| Receivables | - | 5.99M | 6.05M | 3.69M | 4.26M |
| Total Liabilities | - | 6.91M | 6.65M | 7.35M | 11.44M |
| Current Liabilities | - | 6.66M | 6.54M | 7.35M | 11.21M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 365.00K | 247.00K | 106.00K | 456.00K |
| Total Equity | - | 19.57M | 5.54M | 3.94M | 52.00K |
| Shares Outstanding | - | 102.27M | 103.09M | 111.46M | 120.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -19.61M | -15.70M | -1.53M | -12.85M |
| Investing Cash Flow | - | -4.00M | -1.25M | -71.00K | 3.04M |
| Financing Cash Flow | - | -55.00K | 40.00K | 4.50M | 10.01M |
| Capital Expenditure | -22.00K | - | - | -19.00K | -21.00K |
| Free Cash Flow | - | -19.61M | -15.70M | -1.54M | -12.87M |
| Net Change in Cash | - | -23.67M | -16.91M | 2.91M | 202.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -78.7% | -319.6% | -301.4% | -35,444.2% |
| ROCE % | - | -73.6% | -318.6% | -401.3% | -7,388.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLSA
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal fo…
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductio…
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitati…
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal fo…
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with topline …
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Top line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June …
TLSA — Frequently Asked Questions
What is the current share price of TLSA?
As of 2026-08-05 17:25 PDT, TLSA trades at $0.99 on NASDAQ/NYSE. Its 52-week range is $0.89 to $2.46.
What is the market capitalisation of TLSA?
TLSA has a market capitalisation of $119.30M on NASDAQ/NYSE.
What is the P/E ratio of TLSA?
TLSA trades at a trailing price-to-earnings (P/E) ratio of -6.19.
Is TLSA a good stock to buy?
This page provides a data-driven analysis of TLSA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.